RxDoctor Payments Data

Chad Mayer, DO

Allergy · Farmington Hills, MINPI 1467423855

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. ARS Pharmaceuticals Operations, Inc. accounts for 72.8% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $21,342, more than ten times the $587 reported in 2019. Among allergy clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,181in general payments, 2019–2025

Across 341 payments — averaging $73.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ARS Pharmaceuticals Operations, Inc.$18K
  • Sanofi$1K
  • GSK$972
  • AstraZeneca$919
  • CSL Behring$758
  • Regeneron Healthcare Solutions, Inc.$651
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$14,80059%
  • Travel & lodging$2,63110%
  • Food & beverage$7,57230%
  • Education$1781%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,181 in reported general payments places this provider in the 95th percentile of 22 allergy providers in Michigan.

See all allergy providers in Michigan

Medicare billing

Part B allowed, 2024
$16,778
Medicare patients
49
Services billed
964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab17$46,258
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$20,040
Azelastine Hcl27$926
Albuterol Sulfate HfaAlbuterol Sulfate12$526
Montelukast Sodium20$287
Fluticasone Propionate12$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$972$20,04013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 allergy providers in Michigan.

Other allergy in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →